Patents by Inventor Catherine D. Strader
Catherine D. Strader has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6407207Abstract: The present invention is a cloned human BK-2 bradykinin receptor cloned from a human lung fibroblast cell line. A cDNA clone, also part of the instant invention, encodes a novel 364 amino acid protein (the BK-2 receptor) that has the characteristics of a seven transmembrane domain G-protein coupled receptor. The invention is used to express a BK-2 bradykinin receptor in a host mammalian cell to screen for pharmaceutical antagonists or agonists which bind to or interact with the BK-2 bradykinin receptor protein.Type: GrantFiled: November 8, 1993Date of Patent: June 18, 2002Assignee: Merck & Co., Inc.Inventors: Joseph A. Borkowski, John W. Hess, Catherine D. Strader, Richard W. Ransom
-
Patent number: 6348330Abstract: A recombinant human neurokinin-3 receptor (hereinafter identified as human NK3R) is disclosed which has been prepared by polymerase chain reaction techniques. Also disclosed is the complete sequence of human NK3R complementary DNA; expression systems, including a CHO (chinese hamster ovarian cell line) stable expression system; and an assay using the CHO expression system. Human NK3R can be used in an assay to identify and evaluate entities that bind to the neurokinin-3 receptor.Type: GrantFiled: January 12, 2000Date of Patent: February 19, 2002Assignee: Merck & Co., Inc.Inventors: Tung Ming Fong, Ruey-Ruey C. Huang, Catherine D. Strader
-
Patent number: 6258943Abstract: A recombinant human neurokinin-3 receptor (hereinafter identified as human NK3R) is disclosed which has been prepared by polymerase chain reaction techniques. Also disclosed is the complete sequence of human NK3R complementary DNA; expression systems, including a CHO (chinese hamster ovarian cell line) stable expression system; and an assay using the CHO expression system. Human NK3R can be used in an assay to identify and evaluate entities that bind to the neurokinin-3 receptor.Type: GrantFiled: July 12, 1993Date of Patent: July 10, 2001Assignee: Merck & Co., Inc.Inventors: Tung Ming Fong, Ruey-Ruey C. Huang, Catherine D. Strader
-
Patent number: 6001970Abstract: Modified neuropeptide Y receptors having deletions, replacements or additions in the third intracellular domain are identified and methods of making the modified receptors are provided. The invention includes the modified receptors, assays employing the modified receptors, cells expressing the modified receptors, compounds identified through the use of the modified receptors, including modulators of the receptors, and the use of the compounds to treat conditions, including obesity, diabetes, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.Type: GrantFiled: May 6, 1997Date of Patent: December 14, 1999Assignee: Merck & Co., IncInventors: Margaret A. Cascieri, Douglas John MacNeil, Catherine D. Strader
-
Patent number: 5939263Abstract: A novel mammalian neuropeptide Y receptor and method of making the receptor are provided. The invention includes DNA encoding the receptor, the receptor, assays employing the receptor, cells expressing the receptor, antibodies which bind specifically to the receptor, RNA encoded by the DNA sequence or its complementary sequence, and single-stranded DNA with a sequence complementary to the RNA which encodes the receptor. The receptor and assays employing the receptor are useful for identifying compounds which bind to the receptor, including specific modulators of the receptor. Such compounds are useful for treating a variety of disease conditions, including obesity, diabetes, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.Type: GrantFiled: July 25, 1997Date of Patent: August 17, 1999Assignee: Merck & Co., Ltd.Inventors: Margaret A. Cascieri, Douglas J. MacNeil, Lin-Lin Shiao, David H. Weinberg, Carina P. Tan, David L. Linemeyer, Catherine D. Strader
-
Patent number: 5750826Abstract: A transgenic non-human animal with alterations in a bradykinin B2 receptor gene is prepared by introduction of a gene encoding an altered bradykinin B2 receptor into a host non-human animal.Type: GrantFiled: December 2, 1996Date of Patent: May 12, 1998Assignee: Merck & Co., Inc.Inventors: Joseph A. Borkowski, Howard Y. Chen, John W. Hess, Catherine D. Strader, Myrna E. Trumbauer
-
Patent number: 5621079Abstract: A novel mammalian neuropeptide Y receptor and method of making the receptor are provided. The invention includes DNA encoding the receptor, the receptor, assays employing the receptor, cells expressing the receptor, antibodies which bind specifically to the receptor, RNA encoded by the DNA sequence or its complementary sequence, and single-stranded DNA with a sequence complementary to the RNA which encodes the receptor. The receptor and assays employing the receptor are useful for identifying compounds which bind to the receptor, including specific modulators of the receptor. Such compounds are useful for treating a variety of disease conditions, including obesity, diabetes, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.Type: GrantFiled: April 3, 1995Date of Patent: April 15, 1997Assignee: Merck & Co., Inc.Inventors: Margaret A. Cascieri, David L. Linemeyer, Douglas J. Macneil, Lin-Lin Shiao, Catherine D. Strader, David H. Weinberg, Carina P. Tan
-
Patent number: 5552534Abstract: Compounds are provided which are crossreactive with peptides such as those which bind G-protein-linked receptors, together with preparative and therapeutic methods therefor. The compounds have the general structure: ##STR1## wherein at least one of R.sub.1, R.sub.2, R.sub.3, R.sub.4, or R.sub.5 comprises a functional group which is chemically similar to that found in the peptide of interest.Type: GrantFiled: October 28, 1993Date of Patent: September 3, 1996Assignee: The Trustees of the University of PennsylvaniaInventors: Ralph F. Hirschmann, Kyriacos C. Nicolaou, Sherrie Pietranico, T. R. Reisine, Joseph M. Salvino, Paul Sprengeler, Catherine D. Strader
-
Patent number: 5525712Abstract: Recombinant human neurokinin-1 receptor (human NKIR) is disclosed which has been isolated by polymerase chain reaction techniques. Also disclosed is the complete sequence of human NKIR cDNA, expression systems containing said isolated cDNA, including a CHO (Chinese Hamster Ovarian Cell Line) stable expression systems, and an assay using the CHO eexpression system. NKIR, also known as substance P receptor, can be used in an assay to identify and evaluate entities that bind substance P receptor. The assay can also be used in conjunction with diagnosis and therapy to determine the body fluid concnetration of substance P in arthritis patients.Type: GrantFiled: June 5, 1995Date of Patent: June 11, 1996Assignee: Merck & Co., Inc.Inventors: Tung M. Fong, Catherine D. Strader
-
Patent number: 5484886Abstract: Recombinant human neurokinin-1 receptor (hereinafter identified as human NK1R) has been prepared by polymerase chain reaction techniques. The complete sequence of human NK1R complementary DNA has been identified. Expression systems, including a CHO (chinese hamster ovarian cell line) stable expression system; and an assay using the CHO expression system have been developed. NK1R, also known as substance P receptor, may be used in an assay to identify and evaluate entities that bind to the substance P receptor. The assay may also be used in conjunction with diagnosis and therapy to determine the body fluid concentration of substance P antagonists in arthritis patients.Type: GrantFiled: September 7, 1993Date of Patent: January 16, 1996Assignee: Merck & Co., Inc.Inventors: Tung M. Fong, Catherine D. Strader
-
Patent number: 5336595Abstract: A novel recombinant human neurokinin-1 receptor short form (hereinafter identified as human NK1R sF) is disclosed which has been prepared by polymerase chain reaction techniques. Also disclosed is the complete sequence of human NK1R sF complementary DNA; expression systems, including a CHO (Chinese hamster ovarian cell line) stable expression system; and an assay using the CHO expression system.NK1R sF, can be used in an assay to identify and evaluate entities that bind substance P receptor or NK1R sF. The assay can also be used in conjunction with diagnosis and therapy to determine the body fluid concentration of substance P antagonists in arthritis patients.Type: GrantFiled: May 17, 1991Date of Patent: August 9, 1994Assignee: Merck & Co., Inc.Inventors: Catherine D. Strader, Tung M. Fong